Substance / Medication

Primaquine phosphate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Taste Masking of Primaquine Phosphate: A Comparative Evaluation of Three Taste Masking Agents.
Ankit Galande, Tejashree Gagare, Surbhi Sahu et al. · AAPS PharmSciTech · 2025
PMID: 40500474Observational
Development and validation of UPLC method for determination of primaquine phosphate and its impurities.
Dongre Vaijanath G, Karmuse Pravin P, Rao Pilla Prakasa et al. · J Pharm Biomed Anal · 2008
PMID: 18029132Observational
Formulation and evaluation of taste masked oral reconstitutable suspension of primaquine phosphate.
Shah Punit P, Mashru Rajashree C · AAPS PharmSciTech · 2008
PMID: 18770047ObservationalFull text (PMC)
Receptor-mediated hepatocyte-targeted delivery of primaquine phosphate nanocarboplex using a carbohydrate ligand.
Joshi Vishvesh M, Devarajan Padma V · Drug Deliv Transl Res · 2014
PMID: 25787067Other
Formulation and evaluation of primaquine phosphate taste-masked rapidly disintegrating tablet.
Shah Punit P, Mashru Rajashree C · J Pharm Pharmacol · 2008
PMID: 18812020Other
PHARMACOKINETICS OF PRIMAQUINE PHOSPHATE AFTER A SINGLE ORAL ADMINISTRATION TO AFRICAN PENGUINS ().
Carag Jessica H, Sander Samantha J, Kottyan Jen et al. · J Zoo Wildl Med · 2021
PMID: 33827163Preclinical
Primaquine phosphate induces the apoptosis of ATRA-resistant acute promyelocytic leukemia cells by inhibition of the NF-κB pathway.
Ma Lan, Chen Lianjuan, Li Haoying et al. · J Leukoc Biol · 2020
PMID: 32125014Preclinical
Design, characterization and antimalarial efficacy of PEGylated galactosylated nano lipid carriers of primaquine phosphate.
Baruah Uday Krishna, Gowthamarajan Kuppusamy, Ravisankar Vanka et al. · Artif Cells Nanomed Biotechnol · 2018
PMID: 29087218Preclinical
Toxicological study of the primaquine phosphate loaded chitosan nanoparticles in mice.
Rajera Rampal, Nagpal Kalpana, Singh Shailendra Kumar et al. · Int J Biol Macromol · 2013
PMID: 23973494Preclinical
Biowaiver monographs for immediate-release solid oral dosage forms: primaquine phosphate.
Nair Anita, Abrahamsson Bertil, Barends Dirk M et al. · J Pharm Sci · 2012
PMID: 22161739Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Primaquine phosphate (substance)
SNOMED CT
426320005
UMLS CUI
C0033128

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.